瞬时受体电位通道
TRPV公司
TRPV1型
神经科学
TRPV4型
医学
药理学
TRPM8型
化学
生物
受体
内科学
作者
Maria Beatrice Morelli,Consuelo Amantini,Sonia Liberati,Matteo Santoni,Massimo Nabissi
出处
期刊:Cns & Neurological Disorders-drug Targets
[Bentham Science]
日期:2013-04-01
卷期号:12 (2): 274-293
被引量:35
标识
DOI:10.2174/18715273113129990056
摘要
More than 30 different Transient Receptor Potential channels (TRP) have been identified in mammals and are grouped in 6 families. Members of these subunit families, specifically of the vanilloid TRP (TRPV), melastatin TRP (TRPM), ankyrin TRP (TRPA), polycystin TRP (TRPP) and canonical or classical TRP (TRPC) family, are considered relevant in central nervous system neurodegenerative diseases. In fact, TRP channels have received increased attention in recent years, since they are involved in a broad array of pathways and respond to different environmental stimuli. Preclinical research has identified TRPs involved in hereditary neuropathies as well as in a heterogeneous group of neuronal disorders. Moreover, changes in TRP channel expression and functionality have been associated to diabetic thermal hyperalgesia, painful neuropathies and headache. At the molecular level, TRPs are involved in a wide range of mechanisms regulating osmosis, thermal, stretch, chemical and sensory signaling, highlighting TRPs as potential targets for pharmacological intervention. The area of small molecule TRP agonists/antagonists drug development is moving rapidly. This review will evaluate current evidence that supports particular TRP channels as targets for novel drugs, summarizing the current perspectives for the therapeutic potential of TRP agonists and antagonists in the treatment of a wide range of neuropathies, along with potential adverse effects that may limit drug development.
科研通智能强力驱动
Strongly Powered by AbleSci AI